Literature DB >> 2861823

Histamine H2-receptor antagonistic action of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)acetoxyacetamide hydrochloride (TZU-0460).

M Tarutani, H Sakuma, K Shiratsuchi, M Mieda.   

Abstract

The antagonism of histamine H2-receptor by N-(3-[3-(1-piperidinylmethyl)phenoxy)propyl)acetoxyacetamide hydrochloride (TZU-0460) was estimated on isolated guinea-pig right atrium and rat uterus in vitro and on gastric acid secretion in dog with Heidenhain pouch. The concentration-response curves for the positive chronotropic effect of histamine and dimaprit (S-[3-(N,N-dimethylamino) propyl]isothiourea) on atrium were displaced to the right in parallel without change in the maximum response by TZU-0460 with pA2 values of 6.56 and 6.74 and also for the relaxant effect on uterus with pA2 values of 6.81 and 6.65, respectively. There was no significant difference between the estimated pA2 values for TZU-0460 on the different tissues against the same agonist, and also between the pA2 values on the same tissue against the different agonists. The slope of the regression line of log (DR-1) against log TZU-0460 concentration on either tissue was not significantly different from unity; 0.98 (95% confidence limits, 0.81-1.14) on atrium, 0.95 (0.56-1.34) on uterus. These results indicate that TZU-0460 is a competitive antagonist of histamine and dimaprit in vitro. In Heidenhain pouch dog, TZU-0460 also competitively antagonized the stimulation of acid secretion by histamine with pA2 of 6.59 and by dimaprit with pA2 of 6.52, calculated on infused rates. These results indicate that TZU-0460 was about 6 times more potent than cimetidine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861823

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

1.  Early effects of oral administration of omeprazole and roxatidine on intragastric pH.

Authors:  Hiroshi Iida; Shingo Kato; Yusuke Sekino; Eiji Sakai; Takashi Uchiyama; Hiroki Endo; Kunihiro Hosono; Yasunari Sakamoto; Koji Fujita; Masato Yoneda; Tomoko Koide; Hirokazu Takahashi; Chikako Tokoro; Ayumu Goto; Yasunobu Abe; Noritoshi Kobayashi; Kensuke Kubota; Eiji Gotoh; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  J Zhejiang Univ Sci B       Date:  2012-01       Impact factor: 3.066

Review 2.  A review of the animal pharmacology of roxatidine acetate.

Authors:  J Scholtholt; M Bickel; A W Herling
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Clinical studies on the use of roxatidine acetate for the treatment of peptic ulcer in Japan.

Authors:  M Inoue
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.

Authors:  D Murdoch; D McTavish
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

5.  Inhibition of 14C-aminopyrine accumulation in isolated rabbit gastric glands by the H2-receptor antagonist HOE 760 (TZU-0460).

Authors:  A W Herling; M Becht; W Kelker; M Ljungström; M Bickel
Journal:  Agents Actions       Date:  1987-02

6.  Pharmacokinetics of TZU-0460, a new H2-receptor antagonist, in patients with impaired renal function.

Authors:  T Takabatake; H Ohta; Y Yamamoto; Y Ishida; H Hara; S Nakamura; Y Ushiogi; S Satoh; N Hattori
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.